230 related articles for article (PubMed ID: 7505563)
1. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
Stoner E
Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563
[TBL] [Abstract][Full Text] [Related]
2. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
[TBL] [Abstract][Full Text] [Related]
3. 5alpha-reductase inhibitors/finasteride.
Stoner E
Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
[TBL] [Abstract][Full Text] [Related]
4. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
5. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
[TBL] [Abstract][Full Text] [Related]
7. Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study.
Lukkarinen O; Lehtonen T; Talja M; Lundstedt S; Tiitinen J; Taari K
Ann Chir Gynaecol; 1999; 88(4):299-303. PubMed ID: 10661828
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of benign prostatic hyperplasia with finasteride. Results after 7 years of follow-up].
Martínez Sarmiento M; Cuñat Albert E; López Alcina E; Pontones Moreno JL; Sanz Chinesta S; Jiménez Cruz JF
Actas Urol Esp; 1997 Feb; 21(2):105-10. PubMed ID: 9214205
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
Tveter KJ; Beisland HO; Andersen JT; Wolf H; Ekman P; Johansson JE; Kontturi M; Lehtonen T
Tidsskr Nor Laegeforen; 1996 Nov; 116(27):3226-30. PubMed ID: 9011975
[TBL] [Abstract][Full Text] [Related]
10. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
Andersen JT; Wolf H; Ekman P; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
Ugeskr Laeger; 1996 Sep; 158(36):5030-5. PubMed ID: 8928243
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
[TBL] [Abstract][Full Text] [Related]
12. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J;
J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
[TBL] [Abstract][Full Text] [Related]
14. [New prospective therapy for benign prostatic hyperplasia with finasteride].
Miano L; Manieri C; Paradiso Galatioto G; Vicentini C
Riv Eur Sci Med Farmacol; 1993; 15(2):111-9. PubMed ID: 7513437
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review.
Ekman P
Arch Esp Urol; 1994 Nov; 47(9):883-7; discussion 887-8. PubMed ID: 7530944
[TBL] [Abstract][Full Text] [Related]
16. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
17. Finasteride in the treatment of benign prostatic hyperplasia.
Ekman P; Andersen JT; Wolf H
Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
[TBL] [Abstract][Full Text] [Related]
18. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
Magoha GA
East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
20. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
